Table 2.

Relationship between prognosis-related immunity genes and clinicopathologic parameters.

Gene		Gender (Male/Female)	Grade (G1-2/G3-4)	Stage (I-II/III-IV)	T stage (T1-T2/T3-T4)	N stage (N0/N1-X)	M stage (M0/M1-X)
N		318/162	221/257	292/185	310/170	213/267	382/96
CCL7	t-value	0.762	1.639	2.691	2.525	0.429	2.021
	P-value	0.447	0.102	0.007	0.012	0.668	0.044
CHGA	t-value	0.675	3.595	3.451	3.374	0.156	1.773
	P-value	0.500	<0.001	<0.001	<0.001	0.876	0.077
CMA1	t-value	1.409	4.590	6.814	5.772	0.602	5.487
	P-value	0.160	<0.001	<0.001	<0.001	0.548	<0.001
CRABP2	t-value	0.868	1.396	3.088	3.076	0.785	0.361
	P-value	0.386	0.163	0.002	0.002	0.433	0.718
IFNE	t-value	2.200	4.068	3.040	3.204	1.142	0.483
	P-value	0.028	<0.001	0.003	0.001	0.254	0.630
ISG15	t-value	1.798	3.798	4.804	3.621	1.252	3.732
	P-value	0.073	<0.001	<0.001	<0.001	0.211	<0.001
NPR3	t-value	2.240	4.513	3.996	3.713	0.369	3.714
	P-value	0.026	<0.001	<0.001	<0.001	0.713	<0.001
PDIA2	t-value	0.549	3.560	5.851	4.853	1.238	4.614
	P-value	0.584	<0.001	<0.001	<0.001	0.216	<0.001
PGLYRP2	t-value	0.281	1.465	4.133	3.278	0.744	1.501
	P-value	0.779	0.144	<0.001	0.001	0.457	0.134
PLA2G2A	t-value	0.615	4.946	5.338	6.165	0.778	1.104
	P-value	0.539	<0.001	<0.001	<0.001	0.437	0.270
SAA1	t-value	3.231	6.930	7.382	6.598	0.454	4.251
	P-value	0.001	<0.001	<0.001	<0.001	0.650	<0.001
TEK	t-value	1.054	6.582	5.976	4.897	2.068	5.338
	P-value	0.292	<0.001	<0.001	<0.001	0.039	<0.001
TGFA	t-value	1.761	3.349	3.547	2.953	1.217	5.708
	P-value	0.079	<0.001	<0.001	0.003	0.224	<0.001
TNFSF14	t-value	1.523	6.451	4.582	3.850	0.920	2.008
	P-value	0.128	<0.001	<0.001	<0.001	0.358	0.045
UCN2	t-value	0.666	3.796	4.727	4.528	0.042	2.060
	P-value	0.506	<0.001	<0.001	<0.001	0.966	0.040